Madusha Meemanage1, Lindsay C Spender1, Diane Collinson2, Joanna Iannetta1, Pranavi Challapalli1, Julie Turbitt2, Caroline Clark2, Mark Baxter1, Graeme Murray3, Shaun Walsh4, Zofia Miedzybrodzka2, Russell D Petty5. 1. Medical Oncology Group (Level 7, Corridor C), Division of Molecular and Clinical Medicine, Ninewells Hospital and School of Medicine, University of Dundee, James Arnott Drive, Dundee, DD1 9SY, UK. 2. Medical Genetics, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB25 2ZD, UK. 3. Pathology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. 4. Department of Pathology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. 5. Medical Oncology Group (Level 7, Corridor C), Division of Molecular and Clinical Medicine, Ninewells Hospital and School of Medicine, University of Dundee, James Arnott Drive, Dundee, DD1 9SY, UK. r.petty@dundee.ac.uk.
Abstract
PURPOSE: Oesophageal squamous cell carcinoma (ESCC) has a poor prognosis. Advanced tumours are treated with fluoropyrimidine/platinum chemotherapy followed by irinotecan or taxane monotherapy, but resistance is common and new treatments are needed. Approximately 20% of ESCCs carry copy number gain (CNG) of the epidermal growth factor receptor (EGFR) gene. Previous trials show that while anti-EGFR monotherapy benefits biomarker-selected patients with EGFR CNG and/or high EGFR expression, combining anti-EGFR therapies with platinum fluoropyrimidine chemotherapies is not effective, and uncertainty remains regarding the optimal cytotoxic chemotherapy partner for anti-EGFR therapies in ESCC. METHODS: The effects of EGFR CNG on fluoropyrimidine/platinum chemotherapy sensitivity in a cohort of gastroesophageal cancer patients (n = 302) was evaluated. Drug combination studies using the EGFR inhibitor gefitinib with cytotoxic chemotherapies, docetaxel, cisplatin, oxaliplatin and irinotecan, on cell proliferation and cell death of EGFR CNG ESCC cell lines were assessed. RESULTS: EGFR CNG in gastroesophageal cancer patients was associated with improved overall survival following fluoropyrimidine/platinum chemotherapy. However, co-administration of gefitinib and oxaliplatin or cisplatin was frequently antagonistic in cell-based assays in EGFR CNG ESCC, whereas the combination of gefitinib with docetaxel or irinotecan was more efficacious. Co-administration of gefitinib/docetaxel and sequential administration of docetaxel before gefitinib showed synergy, but docetaxel given after gefitinib was antagonistic. CONCLUSION: Gefitinib/platinum co-administration demonstrated antagonism suggesting a possible explanation for the lack of benefit from addition of anti-EGFR therapies to fluoropyrimidine/platinum chemotherapy in trials. Gefitinib/docetaxel co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR therapies in EGFR CNG-positive ESCC, but careful consideration of drug scheduling is required.
PURPOSE:Oesophageal squamous cell carcinoma (ESCC) has a poor prognosis. Advanced tumours are treated with fluoropyrimidine/platinum chemotherapy followed by irinotecan or taxane monotherapy, but resistance is common and new treatments are needed. Approximately 20% of ESCCs carry copy number gain (CNG) of the epidermal growth factor receptor (EGFR) gene. Previous trials show that while anti-EGFR monotherapy benefits biomarker-selected patients with EGFR CNG and/or high EGFR expression, combining anti-EGFR therapies with platinum fluoropyrimidine chemotherapies is not effective, and uncertainty remains regarding the optimal cytotoxic chemotherapy partner for anti-EGFR therapies in ESCC. METHODS: The effects of EGFR CNG on fluoropyrimidine/platinum chemotherapy sensitivity in a cohort of gastroesophageal cancerpatients (n = 302) was evaluated. Drug combination studies using the EGFR inhibitor gefitinib with cytotoxic chemotherapies, docetaxel, cisplatin, oxaliplatin and irinotecan, on cell proliferation and cell death of EGFR CNG ESCC cell lines were assessed. RESULTS:EGFR CNG in gastroesophageal cancerpatients was associated with improved overall survival following fluoropyrimidine/platinum chemotherapy. However, co-administration of gefitinib and oxaliplatin or cisplatin was frequently antagonistic in cell-based assays in EGFR CNG ESCC, whereas the combination of gefitinib with docetaxel or irinotecan was more efficacious. Co-administration of gefitinib/docetaxel and sequential administration of docetaxel before gefitinib showed synergy, but docetaxel given after gefitinib was antagonistic. CONCLUSION:Gefitinib/platinum co-administration demonstrated antagonism suggesting a possible explanation for the lack of benefit from addition of anti-EGFR therapies to fluoropyrimidine/platinum chemotherapy in trials. Gefitinib/docetaxel co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR therapies in EGFR CNG-positive ESCC, but careful consideration of drug scheduling is required.
Authors: Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544
Authors: Aarif Ahsan; Susan M Hiniker; Susmita G Ramanand; Shyam Nyati; Ashok Hegde; Abigail Helman; Radhika Menawat; Mahaveer S Bhojani; Theodore S Lawrence; Mukesh K Nyati Journal: Cancer Res Date: 2010-03-09 Impact factor: 12.701
Authors: Shumei Kato; Aaron Goodman; Vighnesh Walavalkar; Donald A Barkauskas; Andrew Sharabi; Razelle Kurzrock Journal: Clin Cancer Res Date: 2017-03-28 Impact factor: 12.531
Authors: Susan J Dutton; David R Ferry; Jane M Blazeby; Haider Abbas; Asa Dahle-Smith; Wasat Mansoor; Joyce Thompson; Mark Harrison; Anirban Chatterjee; Stephen Falk; Angel Garcia-Alonso; David W Fyfe; Richard A Hubner; Tina Gamble; Lynnda Peachey; Mina Davoudianfar; Sarah R Pearson; Patrick Julier; Janusz Jankowski; Rachel Kerr; Russell D Petty Journal: Lancet Oncol Date: 2014-06-17 Impact factor: 41.316